Lexeo Unveils Porcine TNNI3 Model and 10L-200L AAV Scale-Up at ASGCT
Lexeo will present seven oral and poster abstracts on its cardiac gene therapy pipeline and optimized Sf9-baculovirus AAV manufacturing platform at the ASGCT Annual Meeting, May 11-15, 2026 in Boston. Key data include porcine TNNI3 cardiomyopathy model results, comparability of HEK293 vs Sf9 suspension AAVrh.10 processes, and 10L-to-200L AAV scale-up.
1. Presentation Overview
Lexeo is scheduled to deliver seven presentations—four oral and three poster—at the 29th ASGCT Annual Meeting in Boston from May 11-15, 2026. Topics span cardiac and neurologic gene therapies, preclinical large animal studies, potency assays and next-generation sequencing in manufacturing.
2. Manufacturing Platform Progress
Two presentations focus on AAV production: one demonstrates comparability between adherent HEK293 and Sf9 baculovirus suspension AAVrh.10 clinical manufacturing processes, and another shows scale-up of the Sf RVN baculovirus platform from 10 L to 200 L, underscoring advances toward cost-effective, large-scale vector production.
3. Preclinical Cardiac Programs
Lexeo will present preclinical data on its TNNI3 gene therapy in a porcine cardiomyopathy model, highlighting vector delivery and functional outcomes. Additional sessions cover safety and preliminary efficacy of LX2006 for Friedreich ataxia cardiomyopathy and direct versus CSF delivery approaches for neurologic manifestations.